RxDoctor Payments DataLook up a doctor →

John Valentine, MD

Gastroenterology · Salt Lake City, UTNPI 1144263419

Payments from drug & device makers

$2,191,837in general payments, 2019–2025

Across 283 payments — averaging $7745.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$594K
  • Genentech, Inc.$559K
  • AbbVie$252K
  • Roche Products Limited$245K
  • Boehringer Ingelheim International GmbH$152K
  • AstraZeneca$96K
  • plus $294K from 12 others

What the payments were for

  • Consulting fees$2,45027%
  • Speaking & faculty fees$5,00056%
  • Food & beverage$1,41916%
  • Education$801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,191,837 in reported general payments places this provider in the 95th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$15,578
Medicare patients
67
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab51$1,511,594
Humira(Cf) PenAdalimumab13$144,518
Xeljanz XrTofacitinib Citrate13$75,577
Mesalamine20$8,002
Sulfasalazine26$1,197
Azathioprine19$1,140
Omeprazole33$259
Ciprofloxacin Hcl26$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$49$1,511,59451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →